PK–PD Bedside Bridge (One Page)
You don’t need a lab coat to connect what you see at the bedside to what the drug is doing in the body. This quick “bridge” helps you go from clues → likely PK/PD reason → smart next step.
Tiny cheat sheet:
- PK (pharmacokinetics) = what the body does to the drug (absorption, distribution, metabolism, excretion). Think: drug level over time.
- PD (pharmacodynamics) = what the drug does to the body (receptor effect, sensitivity). Think: effect at a given level.
Two-column bedside bridge
Use this as a quick pattern matcher.
| (A) What you can observe / measure | (B) Likely PK or PD explanation + what to do next |
|---|
| 1) Delayed effect | |
| Clues: Patient took dose, but relief happens much later than expected. Timing feels “off.” | |
| Measure: Time of dose vs onset; route (PO/IV/IM); gut function; pain score or symptom timeline. | Usually PK: slow absorption or slow distribution |
- PO drug with slow gastric emptying, constipation, ileus, food delay, or poor perfusion → delayed absorption.
- Some drugs have a slow “effect site” equilibration (brain effect lags behind blood).
Do next: Verify timing/route; review food/enteral feeds; consider alternate route (e.g., IV) if urgent; avoid “stacking” extra doses too early—watch for late overshoot. |
| 2) Excessive sedation / hypotension soon after dose
Clues: Sleepy, RR down, low BP, pinpoint pupils (opioids), confusion, falls.
Measure: RR/SpO₂, BP, sedation scale, pupils; time since dose; renal/hepatic labs if available. | PK or PD (often both): too much effect
- PK: high peak level (fast IV push), accumulation (renal/hepatic impairment), long half-life, active metabolites.
- PD: increased sensitivity (older age, CNS disease), additive effects with other sedatives.
Do next: Hold/reduce dose; slow administration; check med list for other CNS depressants; consider reversal per protocol when indicated (e.g., naloxone for opioid toxicity); escalate monitoring (airway/respiratory support as needed). |
| 3) No response / lack of effect
Clues: Symptoms unchanged despite “appropriate” dosing.
Measure: Confirm dose/time/route actually taken; symptom scale; vitals (e.g., BP, HR); relevant labs (e.g., INR for warfarin). | Could be PK (not enough drug) or PD (drug can’t produce effect)
- PK: nonadherence, vomiting, poor absorption, wrong technique (inhaler), rapid metabolism, underdosing, drug–drug interaction lowering levels.
- PD: wrong diagnosis/target (antibiotic doesn’t cover bug), receptor tolerance, disease too severe.
Do next: Confirm administration and technique; review timing and expectations (onset may take days); check for interactions; consider level monitoring if available; reassess diagnosis/target and adjust therapy. |
| 4) Wears off too early (“end-of-dose failure”)
Clues: Feels good… then symptoms return consistently before next scheduled dose.
Measure: Symptom diary vs dosing schedule; trough timing; check if doses are spaced too far apart. | Usually PK: level drops below effective range before next dose
- Short half-life, fast clearance, or inadequate dosing interval.
- Sometimes PD tolerance contributes.
Do next: Consider shorter interval, extended-release formulation, or add a planned “breakthrough” dose (per protocol); avoid simply escalating single doses if peaks cause side effects. |
| 5) Rebound symptoms after stopping (or after missed doses)
Clues: Symptoms return worse than baseline after abrupt stop or missed doses (e.g., anxiety, hypertension, tachycardia, insomnia).
Measure: Timing since last dose; HR/BP; withdrawal scales if used; med history (duration of therapy). | PD: body adapted (withdrawal/receptor upregulation)
- With chronic use, the body “resets” its baseline. Removing the drug suddenly can cause overshoot.
Do next: Don’t restart blindly at a huge dose—resume safely and consider taper plan; treat acute symptoms; educate patient about consistent dosing; flag higher-risk meds (e.g., beta-blockers, clonidine, benzodiazepines, opioids, steroids). |
| 6) Suspected drug–drug interaction
Clues: New med started and suddenly: too much effect (toxicity) or too little effect (failure).
Measure: Start dates, dose changes, OTC/herbals; relevant labs (INR, glucose, drug levels where applicable). | Usually PK: metabolism/transport changed (or PD additive/opposing)
- PK: enzyme inhibition ↑ levels; enzyme induction ↓ levels.
- PD: additive effects (two sedatives), opposing effects (NSAID reducing antihypertensive effect).
Do next: Map the timeline (“what changed when?”); check interaction resources; adjust doses or choose alternatives; increase monitoring temporarily (vitals, labs, sedation, ECG if QT risk). |
| 7) Missed doses or irregular timing
Clues: Unstable control, “rollercoaster” symptoms, inconsistent vitals/labs.
Measure: Reconcile MAR vs patient report; pharmacy refill history; barriers (cost, side effects, confusion). | PK: peaks and troughs from inconsistent exposure
- Missed doses drop levels below effective range; double-dosing can cause peaks/toxicity.
Do next: Use a non-judgmental adherence check (“many people miss doses…”); simplify regimen (once daily, blister packs), address side effects, align with routines; document barriers and involve pharmacy/care team. |
| 8) Unexpected toxicity even at “normal” dose
Clues: Side effects out of proportion: bleeding, arrhythmia, confusion, severe nausea, severe hypoglycemia, etc.
Measure: Renal function (eGFR/Cr), liver tests, albumin, weight/frailty, drug levels if available; genetic risk if known. | PK: accumulation or altered free drug; PD: heightened sensitivity
- Reduced clearance (kidney/liver), low albumin → more free drug for some meds, drug accumulation.
- PD sensitivity increases in frailty/older age.
Do next: Check organ function and dose-adjust; consider therapeutic drug monitoring where applicable; switch to safer alternatives; escalate if severe (antidotes, supportive care). |
Quick “timing clues” you can use immediately
- Minutes to hours after dose: think peak-related PK (too fast/too high) or immediate PD sensitivity.
- Days after starting: think accumulation (long half-life) or delayed PD (some effects need time).
- Right before the next dose: think trough too low (wearing off).
- After stopping: think withdrawal/rebound (PD adaptation).
Documenting + communicating concerns (clean and actionable)
When you escalate to a prescriber or team, aim for a crisp story:
- What happened: specific symptoms + severity (not just “not doing well”).
- When: dose time, onset time, trend over time.
- Objective data: vitals, sedation score, key labs, urine output, glucose, ECG findings—whatever fits.
- Medication context: new meds, dose changes, missed doses, route changes, OTC/herbals.
- Your concern + request: “I’m concerned about accumulation/interaction; can we hold the next dose, check renal function, and consider dose adjustment or alternative?”
Takeaway
At the bedside, you’re basically doing detective work: timeline + measurements point you toward PK (levels over time) or PD (sensitivity/target effect)—and that guides the next safe step. Keep it simple, stay curious, and let the pattern do the heavy lifting.
